Capstone Therapeutics Corp. (NASDAQ:CAPS) Sees Large Growth in Short Interest

Capstone Therapeutics Corp. (NASDAQ:CAPS) was the target of a significant growth in short interest during the month of March. As of March 13th, there was short interest totaling 157,346 shares, a growth of 52.5% from the February 26th total of 103,151 shares. Based on an average trading volume of 507,332 shares, the short-interest ratio is currently 0.3 days. Approximately 4.2% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Capstone Therapeutics in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Capstone Therapeutics stock. World Investment Advisors acquired a new position in shares of Capstone Therapeutics Corp. (NASDAQ:CAPS) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 29,000 shares of the company’s stock, valued at approximately $38,000. World Investment Advisors owned 0.40% of Capstone Therapeutics as of its most recent SEC filing. 2.55% of the stock is owned by hedge funds and other institutional investors.

Capstone Therapeutics Price Performance

CAPS stock opened at $0.63 on Friday. The company has a market cap of $5.75 million, a PE ratio of -0.67 and a beta of -1.23. The company has a current ratio of 0.95, a quick ratio of 0.35 and a debt-to-equity ratio of 0.29. The stock has a 50-day moving average price of $0.64 and a two-hundred day moving average price of $0.86. Capstone Therapeutics has a 12-month low of $0.49 and a 12-month high of $3.29.

Capstone Therapeutics Company Profile

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.